WordNet

immunogen consisting of a suspension of weakened or dead pathogenic cells injected in order to stimulate the production of antibodies (同)vaccinum

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

Sentinel surveillance for influenza and other respiratory viruses in Côte d'Ivoire, 2003-2010.

Kadjo HA, Ekaza E, Coulibaly D, Kouassi DP, Nzussouo NT, Kouakou B, Ouattara A, Adjogoua EV, Akoua-Koffi CG, Elia GA, Victoir K, Bretin-Dosso MC, Mott JA.SourceRespiratory virus unit, Department of epidemic virus and National Influenza Centre, Pasteur Institute, Abidjan, Côte d'Ivoire. Institut National de l'Hygiène Publique, Service de la surveillance èpidèmiologique, Abidjan, Côte d'Ivoire. Influenza Division, Centers for Disease Control and Prevention, Accra, Ghana. U.S. Naval Medical Research Unit No.3 (NAMRU-3/GDDRP) Noguchi Memorial Institute for Medical Research (NMIMR). Division vaccins, Sanofi Aventis - Pasteur, Abidjan, Côte d'Ivoire. Institut Pasteur de Paris, Direction des affaires Internationales, Paris, France. Influenza Program Director, U.S. Centers for Disease Control and Prevention, Nairobi, Kenya.
Influenza and other respiratory viruses.Influenza Other Respi Viruses.2013 May;7(3):296-303. doi: 10.1111/j.1750-2659.2012.00389.x. Epub 2012 Aug 2.
Background Many countries in Africa have lacked sentinel surveillance systems for influenza and are under-represented in data used for global vaccine strain selection. Objectives We describe 8 years of sentinel surveillance data and the contribution of influenza and other viruses to medicall
PMID 22863403

Influence of antigen insertion site and vector dose on immunogenicity and protective capacity in sendai virus-based human parainfluenza virus type 3 vaccines.

Mason JN, Elbahesh H, Russell CJ.SourceDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Journal of virology.J Virol.2013 May;87(10):5959-69. doi: 10.1128/JVI.00227-13. Epub 2013 Mar 20.
Recombinant Sendai virus (rSeV) was used as a live, attenuated vaccine vector for intranasal inoculation and mucosal expression of the hemagglutinin-neuraminidase (HN) surface glycoprotein of human parainfluenza virus type 3 (HPIV3). Two vaccine candidates rSeV-HPIV3HN(P-M) and rSeV-HPIV3(F-HN) were
PMID 23514887

Single-Dose Vaccination of a Recombinant Parainfluenza Virus 5 Expressing NP from H5N1 Virus Provides Broad Immunity against Influenza A Viruses.

Li Z, Gabbard JD, Mooney A, Gao X, Chen Z, Place RJ, Tompkins SM, He B.SourceDepartment of Infectious Diseases, University of Georgia College of Veterinary Medicine, Athens, Georgia, USA.
Journal of virology.J Virol.2013 May;87(10):5985-93. doi: 10.1128/JVI.00120-13. Epub 2013 Mar 20.
Influenza viruses often evade host immunity via antigenic drift and shift despite previous influenza virus infection and/or vaccination. Vaccines that match circulating virus strains are needed for optimal protection. Development of a universal influenza virus vaccine providing broadly cross-protect
PMID 23514880

A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys